The mortality associated with post-transplant lymphoproliferative disorder (PTLD) induced by EBV infection can be reduced by monitoring EBV by polymerase-chain-reaction and rituximab given pre-emptively. We performed a retrospective analysis of the risk factors for the occurrence of EBV infection/disease and EBV-related mortality among 273 consecutive recipients of a T-cell-depleted allo-SCT during two periods: (a) before the implementation of a comprehensive protocol (2006)(2007)(2008) and (b) afterwards (2009)(2010)(2011). EBV infection was detected in 61 (22%) cases, and 28 cases were considered to have had EBV disease. Treatment with antithymocyte globulin was the most important risk factor (odds ratio (OR) 2.4; 95% confidence interval (CI) 1.3-4.2, P ¼ 0.001). After implementation of the protocol, in patients experiencing EBV infection, pre-emptive therapy was started more often and sooner (median 3 vs 6 days, P ¼ 0.002). Moreover, there were fewer cases of monomorphic PTLD (4/33 (12%) vs 11/28 (39%), P ¼ 0.01), and the EBV-related mortality was lower for patients experiencing EBV infection (2/33 (6%) vs 8/28 (29%), OR 0.2; 95% CI 0.05-0.9, P ¼ 0.03). The EBV protocol proved feasible and resulted in faster initiation of pre-emptive therapy, the diagnosis in an earlier stage of EBV disease, and decreased EBV-related mortality.
INTRODUCTION
The success of allogeneic haematopoietic SCT (HSCT) can be hampered by the occurrence of post-transplant lymphoproliferative disorder (PTLD) induced by EBV infection (EBV-PTLD), which is associated with increased morbidity and mortality. [1] [2] [3] Although the incidence of EBV-PTLD is generally below 1% following allo-SCT, it may dramatically increase among recipients of transplants from mismatched or unrelated donors, and if T-cell depletion is used or intensive immune-suppression is given either to prevent or treat graft-versus-host disease (GVHD). [4] [5] [6] Other risk factors include previous splenectomy and recipient EBV seronegativity. 7 Treatment of EBV-PTLD relies upon improving the immune response and targeting EBV-infected B cells, rather than relying on anti-viral therapies, as these have not been particularly effective. 3, 8 Reducing immune suppression is one of the pillars of treatment, but its efficacy is limited in the setting of SCT. Use of rituximab to reduce CD20 þ cells forms a second pillar and appears most effective when employed early. 9 However, combination immune-chemotherapy may be required to treat monomorphic PTLD. 10, 11 Novel approaches have been designed to enhance the T-cell reactivity, and include the use of DLI and EBV-specific cytotoxic T cells. 12 The development of PTLD is invariably preceded by the occurrence of EBV infection, which can be detected by PCR. Early detection of infection is important as it allows prompt reduction of immune-suppressive treatment and rituximab to be given pre-emptively, and this approach is increasingly being advocated in guidelines for managing high-risk SCT recipients. 9, 13, 14 A cut-off value for PCR of 1000 copies per mL is thought to be predictive of the development of EBV disease. 15, 16 Several studies have shown that EBV monitoring and early treatment is feasible, and can prevent EBV disease. [17] [18] [19] [20] However, most of these studies were small and used different cut-off values to trigger initiation of preemptive rituximab. Moreover, there remains a paucity of data on effective implementation of the guidelines in daily clinical practice.
We employ both ex vivo and in vivo T-cell depletion to help prevent acute GVHD, but therewith the incidence of EBV infection and disease (PTLD) is high affecting B20% and 10% of patients, respectively. Therefore, we introduced a comprehensive protocol in 2009 that incorporated regular monitoring of EBV-DNAaemia and early treatment with rituximab to reduce the incidence of EBV-related complications. We used a retrospective analysis to explore the risk factors for infection and disease at our centre, and evaluated the impact of the protocol on EBV disease and outcome.
PATIENTS AND METHODS

Patient, donor and SCT characteristics
We performed a retrospective analysis on 273 patients who had received an allo-SCT from 2006 to 2011. All patients included had a minimum follow-up of 6 months. The first group (cohort 1) consisted of 148 patients who had received an SCT during 2006-2008, before the introduction of the EBV protocol. The second group (cohort 2) consisted of 125 patients who received their transplant during 2009-2011 after the protocol had been implemented. Details of the treatment and management of the patients have been described previously. [21] [22] [23] There were 159 matched related (MRD), 83 matched unrelated (MUD) and 31 mismatched unrelated (MMUD) donor SCTs. All patients received a graft that had been first depleted of T cells ex vivo and then enriched with 0.5 Â 10 6 CD3 þ /kg. Myeloablative conditioning regimens consisted of CY (60 mg/kg for 2 days) together with either TBI (TBI; 4.5 Gy for 2 days) or BU (4 mg/kg for 4 days). Idarubicin (42 mg/m 2 in 48 h intravenously) was added in some cases to reduce the risk of relapse. 24 Non-myeloablative conditioning regimens consisted mainly of CY (1200 mg/m 2 for 4 days) together with fludarabine (30 mg/m 2 for 4 days). Patients receiving a graft from an unrelated donor received antithymocyte globulin (ATG) (2 mg/kg for 4 days), as a means of in vivo T-cell depletion for GVHD prevention. GVHD prophylaxis consisted of cyclosporine only.
Quantitative PCR for EBV Real-time PCR was performed on plasma samples according to validated procedures, and the primers and probes used have been described earlier. 25 Quantitative results were obtained using standard curves and results were expressed in log 10 (viral copy number/mL).
Definition of EBV infection and disease, and outcome
The definition of EBV infection and disease was based on those proposed by Styczynski et al., 14 with some modifications. Specifically, EBV-DNAaemia was considered synonymous with infection when the PCR for EBV-DNA was Xlog 3 copies/mL. 16, 18 EBV disease was defined as either probable EBV disease (significant lymphadenopathy or other endorgan disease accompanied by a high-EBV load) or proven disease (histologically confirmed EBV positive PTLD or other end-organ disease). In our cohort, EBV disease was always accompanied by EBV infection.
Pre-emptive therapy was defined as rituximab given to a patient with asymptomatic EBV infection. Pre-emptive therapy was designated to be successful when the EBV-DNA copies numbers declined to olog 3 without recurrence, and there were no clinical signs or symptoms consistent with EBV disease. Successful treatment of EBV disease was defined as resolution of all clinical signs and symptoms, and a reduction of EBV-DNA copies numbers to olog 3 without recurrence.
Protocol for monitoring EBV and pre-emptive rituximab Before 2009 there was no explicit protocol, although PCR was done weekly to monitor EBV infection, but interpretation of the results and decisions on treatment were left to the discretion of the individual haematologist. After this time, a protocol on the management of EBV-related complications was introduced (Figure 1 ), which entailed obtaining blood for EBV-PCR once every week for 6 months or for as long as immune-suppressive treatment was required to treat GVHD.
An EBV load olog 3 copies/mL without clinical signs or symptoms was not considered to represent infection, but indicated the need for close monitoring, with a second PCR performed within 2-3 days. When EBV infection (Xlog 3 copies/mL) was detected, lymphadenopathy was investigated by a CT-scan and lymph node resection was performed in case enlarged lymph nodes were detected. Immune-suppressive drugs were to be stopped or tapered whenever possible. Pre-emptive therapy with rituximab was started on the same day, given at a dose of 375 mg/m 2 weekly for a total of four doses. When clinical signs and symptoms suggestive of PTLD were present a CT scan was ordered, a BM biopsy performed, and if feasible an enlarged lymph node was obtained for pathological examination. Simultaneously, immune-suppressive drugs had to be stopped and rituximab started as soon as possible. In case of clinical failure or progression a step-up in the treatment with immune-chemotherapy, radiotherapy and DLI was initiated. Reduced EBV disease-related mortality with pre-emptive rituximab WJFM van der Velden et al
Statistical analysis
The total cohort was analyzed with regard to characteristics of and risk factors for EBV infection and disease. Thereafter, we analyzed the impact of the implementation of our protocol on the incidence of EBV infection and disease, and clinical outcome (cohort 2) by comparing it with the period before (cohort 1). Descriptive statistics were used for the characteristics of patients, donors and SCT procedure. A comparison of variables between patients with and without EBV infection/disease, and between the two cohorts was done using the independent t-test, Mann-Whitney U-test or Fisher's exact test when appropriate. Backward logistic regression analysis was used for the multivariable analysis of risk factors for EBV infection/disease and EBVrelated mortality. EBV-related mortality and non-relapse mortality (NRM) were analyzed for outcome. Kaplan-Meier estimates were calculated per cohort to estimate the cumulative incidence of EBV-related death in patients with EBV infection/disease. Non-relapse mortality (NRM) was compared with the log-rank test, and patients with relapse-related death were considered as censored observations. SAS 9.2 (SAS Institute Inc., Cary, NC, USA) was used for the statistical analysis. A P-value of o0.05 was considered statistically significant.
RESULTS
Analysis of the entire cohort EBV infection and disease incidence. With the use of ex vivo and in vivo T-cell-depleted SCT there was a high risk for EBV complications with an incidence of EBV infection of 22% (61/ 273). Twenty-eight (10%) of these patients experienced either probable (5 cases) or proven EBV disease (23 cases). Most cases occurred within the first 3 months after SCT, with only 10% developing EBV infection or disease 6 months after SCT ( Table 1) . The proven disease was mainly monomorphic PTLD predominantly involving diffuse large B-cell lymphoma (DLBCL) at an advanced stage (stage III-IV Ann-Arbor).
Risk factors for EBV infection and disease. Development of EBV infection/disease was not related to patient or, donor age or gender, the method of ex vivo T-cell depletion, EBV serological status, HLA-mismatch, year of transplantation, the underlying disease or the occurrence of acute GVHD (Table 1) . Only two factors significantly influenced the occurrence of EBV infection and disease namely, donor type and the conditioning regimen used (univariable analysis P ¼ 0.005 and Po0.001, respectively). However, these two factors were inseparable as patients receiving a graft of a (M)MUD always received ATG in their conditioning, and those receiving a MRD graft did so only sporadically. The incidence of EBV infection/disease and probable/proven EBV disease ranged from 9% to 43% and from 2.5% to 26%, respectively (Supplementary Figure 1) .
Multivariable analysis showed that ATG significantly increased the risk for EBV infection/disease (OR 2.4; 95% CI 1.3-4.2, P ¼ 0.001), whereas the intensity of the conditioning regimen (myeloablative vs non-myeloablative) had no impact overall, although differences were seen depending on the use of ATG. Myeloablative conditioning significantly increased the risk of EBV infection/disease in patients who had not received ATG (OR 2.6; 95% CI 1.05-7.15, P ¼ 0.01). By contrast, non-myeloablative conditioning increased the risk for EBV infection/disease to those who had received ATG, though this did not reach statistical significance (OR 2.1; 95% CI 0.92-4.8, P ¼ 0.08).
Treatment and outcome of EBV infection and disease. Most patients with EBV infection and disease (53/61; 87%) received therapy with rituximab, with only a minority eventually receiving combined immune-chemotherapy 9/61 (15.5%). Patients received on average 4 doses of rituximab, although the number ranged from a single dose to 13 doses. Six patients were given DLI, and only one patient received radiotherapy. In patients that received rituximab pre-emptively complete resolution without progression was seen in 90% of the cases (26/29) . Only three patients progressed to EBV disease that required immune-chemotherapy, and with two of them ultimately dying of EBV disease. Treatment of EBV infection or disease was successful in 74% (45/61) cases. Sixteen patients died before resolution, with death being attributed to EBV disease in 10 cases, as the other 6 patients died from another cause with a positive PCR-EBV but no EBV disease. So EBV-related mortality was 16.4% (10/61) for those patients experiencing an EBV infection and 3.7% of the total SCT cohort (Table 1) . Multivariable analysis showed that use of ATG (OR 13.8; 95% CI 1.8-110, P ¼ 0.01), age (OR 1 Table 2 ). There was a greater use of (M)MUD in cohort 2, and hence conditioning including ATG, but the difference did not reach statistical significance. However, there was a higher incidence of PCR EBV Xlog 3 in cohort 2 than in cohort 1 (26% (33/125) vs 19% (28/148), P ¼ 0.1). Nevertheless, the incidence of EBV disease was similar (11% in cohort 1 vs 9.5% in cohort 2) (Supplementary Figure 2) . More patients in cohort 1 developed proven disease with a monomorphic phenotype than was found in cohort 2 (39% (11/28 vs 12% (4/33) P ¼ 0.01).
Changes in therapy.
After the introduction of the EBV protocol, all patients with EBV infection and disease received therapy compared with only 70% in cohort 1 (P ¼ 0.001, Table 2 ). The use of pre-emptive therapy with rituximab increased from 29 to 64%, P ¼ 0.01. Moreover, therapy was initiated significantly sooner, with the median time to starting rituximab decreasing from day 6 to day 3 (P ¼ 0.002). There was no difference in the use of chemotherapy though DLI was used to enhance immunereconstitution more often in cohort 2. Eight patients in cohort 1 did not receive any therapy due to a variety of reasons (Table 2) .
Improved outcome after initiation of the protocol. EBV-related death among patients with EBV infection was significantly lower in cohort 2 compared with cohort 1 (6% (2/33) vs 29% (8/28), OR 0.2; 95% CI 0.05-0.9, P ¼ 0.03, Table 2; Figure 2 ). Only 2 (17%) of the 12 patients with EBV disease died of it in cohort 2 compared with 8 (50%) of the 16 patients in cohort 1. EBV disease-related mortality declined from 5.4% in cohort 1 to 1.6% in cohort 2 (P ¼ 0.1, Supplementary Figure 2) . In patients from cohort 2 who had an EBV infection a trend towards a lower NRM was observed when compared with cohort 1 (log-rank P ¼ 0.09, Figure 3 ).
DISCUSSION
The introduction of a comprehensive protocol for managing EBVrelated complications, in a high-risk SCT setting resulting from the use of T-cell depletion, resulted in a lower EBV disease-related mortality among those experiencing an EBV infection, from 29 to 6% (OR 4.8, P ¼ 0.03). When looking at the total cohort the EBVrelated mortality was also decreased, from 5.4 to 1.6%, but this was NS probably due to the relatively low numbers of EBV deaths (in total 10 events). The impact of the protocol was, however, confirmed in the multivariable analysis that showed a significant impact of the year of transplantation on the occurrence of EBVrelated mortality. This improvement was seen despite an increase in the number of high-risk SCTs during the last 3 years, which had resulted from the increased use of (mis)matched unrelated donors and therewith automatically ATG in the conditioning. EBV loads X log 3 copies/mL were found in more cases after the introduction of the protocol, but this did not result in more EBV disease. The improved outcome was likely related to earlier recognition of patients at risk and faster initiation of pre-emptive rituximab, which prevented progression to overt EBV disease. This was underscored by the fact that more polymorphic PTLD was diagnosed after implementation of the protocol whereas only monomorphic PTLD had been seen before, consistent with EBV disease being 'diagnosed' earlier, which, by extension, resulted in a better chance of treatment success. NRM also appeared lower after implementation of the protocol, and, although the difference did not reach statistical significance, it at least suggests that there was no increasing mortality due to infectious complications that might arise as a result of the more intensive use of rituximab.
The risk factors for EBV infection and disease we identified were consistent with those already known, namely the use of T-cell depletion, which significantly has an impact on the immune- Univariate comparison of variables between patients with and without EBV infection and disease was done using the independent t-test, Mann-Whitney U-test, or Fisher's exact test when appropriate.
b Backward logistic regression analysis was used for the multivariable analysis of risk factors for EBV infection/disease and EBV-related mortality. Only factors with a Pp0.2 on univariable analysis were incorporated in the multivariable analysis.
Reduced EBV disease-related mortality with pre-emptive rituximab WJFM van der Velden et al reconstitution post allo-SCT. 4 EBV infection occurred mainly in the first 6 months post SCT, when there is profound lymphopenia, especially for patients who have received ATG. 5 No other risk factors were found, including HLA-mismatch or EBVserological status. This can be explained by a very low number of recipient negative/donor positive EBV-serological status combinations, and the fact that patients with a MMUD and MUD were treated similarly with both ATG and ex vivo T-cell depletion. 7 The presence of acute GVHD was not a significant risk factor on multivariable analysis, but might have had an influence on patients with a MRD SCT, as myeloablative conditioning resulted in more EBV infection and disease than did nonmyeloablative conditioning, and this was likely explained by a higher incidence of GVHD. However, the numbers were too small to perform a subgroup analysis (data not shown). Combined ex vivo and in vivo T-cell depletion performed for patients receiving (M)MUD SCT markedly increased the risk for EBV complications. In patients receiving ATG non-myeloablative conditioning with fludarabine and CY enhanced the risk in comparison to those with myeloablative conditioning, as the immune-suppression had a greater impact than did the myeloablation. We have now abandoned this conditioning regimen, as the incidence of probable/proven EBV disease was Days from EBV infection EBV-related mortality (%) Figure 2 . EBV-related mortality in patients with EBV infection and disease. Comparison of the cumulative incidence of EBV-related mortality before (cohort 1) and after (cohort 2) implementation of a comprehensive EBV protocol on monitoring and pre-emptive rituximab.
unacceptably high (26%), and have replaced it with a reducedintensity scheme incorporating fludarabine, melphalan, together with alemtuzumab. 26 Our EBV protocol is limited by the fact that it relied on limited evidence. Moreover, there was no standard for the PCR technique at the time nor a threshold that was considered an appropriate trigger for starting pre-emptive therapy. However, a cut-off value of log 3 has been shown to be a good negative predictor for the occurrence of EBV disease, so, at least in high-risk cohorts, using this approach to exclude EBV disease appears safe. 16, 18 This inevitably means there will be overtreatment with rituximab with an additional risk to patients vulnerable for infectious complications and other adverse reactions, such as late-onset neutropenia and pulmonary toxicity, as well as high costs. [27] [28] [29] This last could be reduced if the correct number of doses necessary to control EBV complications was better established since we, like others, gave at least 4 weekly doses of rituximab, although we noted that EBV infection resolved after some patients had received only 1 or 2 rituximab doses. Clearly, some kind of risk assessment is needed to help ensure that those most at risk are effectively treated, while others at low risk are spared from unnecessary treatment. Such a risk score should incorporate predictive factors such as EBV serological status, conditioning regimen, GVHD prophylaxis and immune cell counts. Initiatives are already underway and results are promising so far. 19 Clearly prospective multicentre studies are also necessary but in the meantime the SCT community should adopt a consensus on the formal definitions of EBV disease, as well as on the method for detecting and monitoring EBV.
In conclusion, the introduction of a comprehensive protocol on EBV complications in a high-risk SCT population proved feasible and resulted in faster initiation of pre-emptive therapy, the earlier diagnosis of EBV disease, and lower EBV-related mortality. The risk for overtreatment should not be underestimated, but in the absence of a risk-adapted approach the community should seek consensus on optimal EBV monitoring, the threshold for starting pre-emptive therapy, and the optimal number of doses of rituximab. 
